 |
Video: What is a Stock Split?
|
 |
Kronos Bio, Inc. is a biopharmaceutical company. Co. is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. According to our KRON split history records, Kronos Bio has had 4 splits. | |
 |

Kronos Bio (KRON) has 4 splits in our KRON split history database. The first split for KRON took place on January 30, 1996. This was a 3 for 2
split, meaning for each 2
shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. KRON's second split took place on March 10, 1999. This was a 3 for 2
split, meaning for each 2
shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split. KRON's third split took place on November 16, 2001. This was a 3 for 2 split, meaning for each 2 shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 2250 share position pre-split, became a 3375 share position following the split. KRON's 4th split took place on November 03, 2003. This was a 3 for 2 split, meaning for each 2 shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 3375 share position pre-split, became a 5062.5 share position following the split.
When a company such as Kronos Bio splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the KRON split history from start to finish, an original position size of 1000 shares would have turned into 5062.5 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kronos Bio shares, starting with a $10,000 purchase of KRON, presented on a split-history-adjusted basis factoring in the complete KRON split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/12/2020 |
|
End date: |
02/10/2025 |
|
Start price/share: |
$29.00 |
|
End price/share: |
$0.95 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.73% |
|
Average Annual Total Return: |
-54.58% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$326.91 |
|
Years: |
4.33 |
|
|
 |
Date |
Ratio |
01/30/1996 | 3 for 2
| 03/10/1999 | 3 for 2
| 11/16/2001 | 3 for 2 | 11/03/2003 | 3 for 2 |
|
 |